Date  |
|
| Mar 16, 2021 |
Celcuity Announces Breast Cancer Clinical Trial Collaboration with MD Anderson, Novartis, and Puma Biotechnology to Study New Drug Regimen |
| Apr 8, 2021 |
Celcuity Announces Worldwide Licensing Agreement with Pfizer to Develop and Commercialize Gedatolisib, a First-in-Class PI3K/mTOR Inhibitor for Breast Cancer |
| Apr 8, 2021 |
Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance® and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update |
| Apr 12, 2021 |
Celcuity Presents Data at AACR Annual Meeting Assessing Gedatolisib, a pan-PI3K/mTOR Inhibitor, in HER2-negative Breast and Ovarian Cancer Patient Tumors with Hyperactive RAS Network Signaling |
| Apr 26, 2021 |
Celcuity Inc. Schedules Release of First Quarter 2021 Financial Results and Webcast |
| May 10, 2021 |
Celcuity Inc. Reports First Quarter 2021 Financial Results and Provides Corporate Update |
| Jun 9, 2021 |
Celcuity Announces Appointment of Dr. Igor Gorbatchevsky as VP of Clinical Development and Jill Krause as VP of Clinical Operations |
| Jun 28, 2021 |
Celcuity Announces Launch of Follow-on Offering |
| Jun 28, 2021 |
Celcuity Announces Pricing of Follow-on Offering |
| Jul 8, 2021 |
Celcuity to Participate in the William Blair Biotech Focus Conference |
| Aug 2, 2021 |
Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast |
| Aug 5, 2021 |
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference |
| Aug 9, 2021 |
Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update |
| Oct 18, 2021 |
Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases |
| Oct 29, 2021 |
Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call |